On the heels of Addyi's approval, Sprout scooped up by Valeant
Executive Summary
Valeant Pharmaceuticals International Inc. is paying $1bn in cash--$500mm up front and $500mm in Q1 2016--to acquire Sprout Pharmaceuticals Inc. and gets a share of future profits upon achievement of certain milestones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice